NCT02562183Unknown4 期
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 2,186
- 试验地点
- 7
- 主要终点
- Number of Participants with Adverse Events
研究概览
简要总结
In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects. Subjects will receive kallikrein treatment according to real clinical practice (suggest above 14days treatment) and 90 days follow up
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute anterior circulation cerebral infarction diagnosed ≤ 48h;
- •First time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae(mRS=0-2);
- •Age from 18 to 80 years old;
- •National Institute of Health stroke scale(NIHSS) from 6 to 25;
- •Have provided signed written informed consent from the patient or the patient's legal representative.
排除标准
- •Brain CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.
- •Transient ischemic attack(TIA);
- •Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8;
- •Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time(according to its instruction), or need to be treated with ACEI;
- •Cases treated with thrombolysis / stent surgery or expected to be treated with thrombolysis / interventional therapy / stent surgery.
- •subjects with bleeding disorders at Past or present, laboratory tests: INR > 1.5 or APTT > 2 times;
- •subjects with abnormal liver function (ALT/AST > 1.5 * ULN) and abnormal renal function (Cr> normal upper limit);
- •subjects with history of epilepsy or other serious systemic disease before onset of AIS refused by PI to enroll ;
- •subjects with cardiogenic stroke or cardiogenic stroke related high-risk factors identified by PI, such as atrial fibrillation, echocardiography or Mural thrombus etc;
- •subjects diagnosised any malignancy (except basal cell carcinoma) within 5 years prior to the start of the study;
- •subjects with severe dementia or can't cooperate to evaluate identified by PI;
- •suffering from severe hypertension and failed to control :systolic blood pressure ≥200mmHg (26.6kPa) or diastolic blood pressure ≥110mmHg (14.6kPa); hypotension: systolic blood pressure< 90mmHg and/or diastolic blood pressure< 60mmHg
- •subjects be allergic or intolerant to kallikrein at past;
- •subjects be pregnant/lactating or possibly and planned pregnant;
- •subjects be unsuitable for this clinical study identified by PI.
研究组 & 干预措施
kallikrein group
Experimental
Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
干预措施: kallikrein (Drug)
结局指标
主要结局
Number of Participants with Adverse Events
时间窗: From enrolled to the day 90
次要结局
- Activities of daily living on the Barthel Index(The day 15,22 and 90 after enrolled)
- Patients body status on the Modified Rankin Scale(The day 15, 22 and 90 after enrolled)
- EQ-5D-3L score(The day 15, 22 and 90 after enrolled)
- Evaluation of pharmaceutical economics(The day 15, 22 and 90 after enrolled)
- Cerebral infarction on the National Institute of Health stroke scale(The day 8,15 and 22 after enrolled)
- Recurrence rate of acute cerebral infarction(From enrolled to the day 90)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
4 期
Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke PatientsStroke, AcuteNCT04102956The Second Hospital of Hebei Medical University80
招募中
不适用
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel OcclusionAcute Ischemic StrokeNCT06211712Huashan Hospital120
已完成
4 期
Evaluation Of HUK in Acute Stroke Patients: MRS and CTPAcute Ischemic StrokeNCT03431909Xuanwu Hospital, Beijing80
尚未招募
不适用
Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic StrokeAcute Ischemic StrokeNCT06137300Yi Yang986
终止
1 期
First in Human Study of M1069 in Advanced Solid TumorsMetastatic or Locally Advanced Unresectable Solid TumorsNCT05198349EMD Serono Research & Development Institute, Inc.15